Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tandem Diabetes Care (TNDM) Non-Current Assets (2016 - 2025)

Tandem Diabetes Care's Non-Current Assets history spans 13 years, with the latest figure at $263.0 million for Q4 2025.

  • For Q4 2025, Non-Current Assets rose 8.14% year-over-year to $263.0 million; the TTM value through Dec 2025 reached $1.0 billion, up 21.24%, while the annual FY2025 figure was $263.0 million, 8.14% up from the prior year.
  • Non-Current Assets reached $263.0 million in Q4 2025 per TNDM's latest filing, up from $257.7 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $263.0 million in Q4 2025 to a low of $92.6 million in Q1 2021.
  • Average Non-Current Assets over 5 years is $192.8 million, with a median of $203.5 million recorded in 2022.
  • Peak YoY movement for Non-Current Assets: surged 123.66% in 2022, then dropped 14.75% in 2023.
  • A 5-year view of Non-Current Assets shows it stood at $93.6 million in 2021, then skyrocketed by 116.64% to $202.8 million in 2022, then rose by 0.92% to $204.7 million in 2023, then grew by 18.81% to $243.2 million in 2024, then increased by 8.14% to $263.0 million in 2025.
  • Per Business Quant, the three most recent readings for TNDM's Non-Current Assets are $263.0 million (Q4 2025), $257.7 million (Q3 2025), and $260.9 million (Q2 2025).